ibrutinib als standard bei chronisch lymphatischer leukämie | prof. dr. s. stilgenbauer | ash 18
Published 5 years ago • 923 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:32
neue durchbrüche bei chronisch lymphatischer leukämie | prof. dr. s. stilgenbauer, | ash 18
-
1:37
acalabrutinib may be an alternative to ibrutinib for treatment of cll
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
1:00
ash 2022 lba: results from final analysis of alpine - zanubrutinib vs ibrutinib for r/r cll/sll
-
1:28
overview of resonate-2 clinical trial of ibrutinib in cll
-
6:07
cll: the biologics of ibrutinib therapy
-
0:56
ibrutinib updates from ash 2016
-
1:47
ash cll highlights: ibrutinib-venetoclax combination & undetectable mrd in ighv-mutated patients
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:13
dr. hamlin on early study of ibrutinib/buparlisib in mcl, fl, and dlbcl
-
1:23
comparing ibrutinib efficacy and toxicity levels by age for patients with cll/sll
-
1:38
front-line use of ibrutinib for cll in a real-world setting
-
3:58
phase ib/iia study of azd4573 acalabrutinib in r/r dlbcl
-
29:14
ibrutinib resistance-mechanisms and options in cll
-
1:25
dr. abedin discusses differences between acalabrutinib and ibrutinib in cll
-
1:26
overview of the resonate-2 clinical trial of ibrutinib as front-line therapy
-
1:26
common side-effects of btk inhibitors (ibrutinib and acalabrutinib) in the treatment of cll
-
4:17
ibrutinib in dlbcl: revelations from further analysis of phoenix
-
1:33
understanding the mechanisms of venetoclax and ibrutinib resistance